Repligen Corp Files 8-K on Financials
Ticker: RGEN · Form: 8-K · Filed: May 1, 2024 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Repligen filed an 8-K detailing financial results and exhibits.
AI Summary
Repligen Corporation filed an 8-K on May 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. Repligen Corporation, incorporated in Delaware, is a biological products company based in Waltham, MA.
Why It Matters
This 8-K filing provides crucial updates on Repligen Corporation's financial health and operational results, which can influence investor decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any unusual risks.
Key Players & Entities
- REPLIGEN CORP (company) — Filer
- Delaware (jurisdiction) — State of incorporation
- Waltham, MA (location) — Principal executive offices
- May 1, 2024 (date) — Date of earliest event reported
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on Repligen Corporation's Results of Operations and Financial Condition, and includes Financial Statements and Exhibits.
When was this 8-K filing submitted?
The filing was submitted on May 1, 2024.
What is Repligen Corporation's principal executive office address?
Repligen Corporation's principal executive offices are located at 41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453.
What is Repligen Corporation's IRS Employer Identification Number?
Repligen Corporation's IRS Employer Identification Number is 04-2729386.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-01 07:44:01
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share RGEN The Nasdaq Global Se
Filing Documents
- d780642d8k.htm (8-K) — 24KB
- d780642dex991.htm (EX-99.1) — 162KB
- g780642g0501033859863.jpg (GRAPHIC) — 5KB
- 0001193125-24-126349.txt ( ) — 333KB
- rgen-20240501.xsd (EX-101.SCH) — 3KB
- rgen-20240501_lab.xml (EX-101.LAB) — 18KB
- rgen-20240501_pre.xml (EX-101.PRE) — 11KB
- d780642d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release by Repligen Corporation, dated May 1, 2024 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Date: May 1, 2024 By: /s/ Tony J. Hunt Tony J. Hunt Chief Executive Officer